Actively Recruiting

Age: 2Years - 17Years
All Genders
NCT06138509

Peripheral Serotonin and Albinism

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-09-12

160

Participants Needed

1

Research Sites

103 weeks

Total Duration

On this page

Sponsors

A

Assistance Publique - Hôpitaux de Paris

Lead Sponsor

U

URC-CIC Paris Descartes Necker Cochin

Collaborating Sponsor

AI-Summary

What this Trial Is About

Serotonin (5-HT or 5-hydroxytryptamine) is a monoamine primarily known for its role as a neurotransmitter in the central nervous system (CNS). However, the functions of serotonin go beyond its role in the central nervous system: different peripheral tissues have the capacity to produce and/or use serotonin locally, forming systems called "micro-serotonergic" systems. Among the peripheral roles of serotonin, previous work by the Iron and Immunity team, INSERM U1016, Institut Cochin (Paris), was able to show that serotonin has a positive role on erythropoiesis and the survival of red blood cells, and the team's ongoing work suggests that serotonin also impacts iron metabolism. In humans and in mouse models, several studies have suggested a role for serotonin in pigmentation. In certain syndromic forms of albinism such as Hermansky Pudlak syndrome, platelet serotonin levels are reduced in connection with a decrease in dense platelet granules (delta granules): this characteristic is even part of the diagnostic criteria. Preliminary data from the Iron and Immunity team found: * Changes in serotonin levels in children with albinism compared to control patients, * Changes in hemoglobin level and mean corpuscular volume (MCV) in children with albinism (towards anemia and microcytosis), * Changes in the iron balance in children with albinism (towards iron deficiency). The hypothesis of this research is that peripheral serotonin plays a role in the clinical and biological manifestations of oculocutaneous albinism.

CONDITIONS

Official Title

Peripheral Serotonin and Albinism

Who Can Participate

Age: 2Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with albinism aged 2 to 17 years
  • Followed in the MAGEC-Necker reference center during the inclusion period
  • Informed consent obtained from parental authority holders and patients of understanding age
  • Control patients aged 2 to 17 years who consulted at Necker hospital emergency or surgical services during the inclusion period
  • Control patients with normal complete blood count
  • Control patients with normal C-reactive protein test
  • No opposition from parental authority holders within one month after sending the study information note
Not Eligible

You will not qualify if you...

  • Inability to have a blood test for patients
  • Abnormal blood count for control patients
  • Elevated C-reactive protein above laboratory standard for control patients

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hôpital Necker-Enfants Malades

Paris, France, 75015

Actively Recruiting

Loading map...

Research Team

S

Smail HADJ-RABIA, MD, PhD

CONTACT

H

Hélène Morel

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here